Peptide Disrupts Nav1.8–Ank3 Interaction to Reduce Pain-Like Behaviors in Mice
Published in Brain/Neurology, Drugs development & discovery, Journals.
October 6, 2026 — Boston Children’s Hospital described research published in Cell Reports Medicine investigating a nonopioid approach to neuropathic pain. The work targets an interaction between the sodium channel Nav1.8 and the scaffolding protein ankyrin-G, also called Ank3, in pain-sensing neurons.
According to the hospital’s account, a short lipidated peptide disrupts that interaction, lowers Nav1.8 levels at the cell membrane and reduces heightened neuronal activity. Experiments showed fewer pain-like behaviors in mouse models while preserving acute protective pain.
The hospital has licensed intellectual property from the work to Mimetic Medicines, which is developing investigational long-acting peptide candidates targeting the same interaction.
The evidence remains preclinical. Pain-like behaviors in mice are useful experimental measures, but they do not establish pain relief, safety or preservation of normal sensation in patients. The mechanism offers a direction for drug development that still needs further testing.
Sources: Boston Children’s Hospital research account, October 6, 2026; Cell Reports Medicine study, DOI: 10.1016/j.xcrm.2026.103090.